Johnson & Johnson Q3 sales rise on MedTech growth, lifts 2026 outlook

Johnson & Johnson

13/10/2026 11:31

Overview
US healthcare conglomerate's Q3 sales rose 5.9%, slightly beating analyst expectations
Adjusted EPS for Q3 was $2.59, beating analyst expectations
Company raised 2026 sales and adjusted EPS guidance

Outlook
Johnson & Johnson raises 2026 reported sales guidance to $101.2 bln at midpoint
Company increases 2026 adjusted EPS guidance to $11.10 at midpoint
Johnson & Johnson sees 2026 reported sales growth of 7.4% at midpoint

Result Drivers
PRODUCT LAUNCHES AND ONCOLOGY GROWTH - Co said sales growth was driven by new products in Immunology and strong performance in Oncology and Neuroscience
MEDTECH SALES - MedTech sales growth was led by cardiovascular electrophysiology products, contact lenses, and orthopaedics trauma
SPECIAL CHARGES - Q3 EPS was reduced by one-time charges related to talc litigation, Firefly Bio acquisition, and Sail Biomedicines collaboration

Company press release: ID:nBw5KM8HBa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Slight Beat*
$25.40 bln
$25.28 bln (16 Analysts)
Q3 Adjusted EPS
Beat
$2.59
$2.54 (16 Analysts)
Q3 EPS
 
$0.09
 
Q3 Net Income
 
$210 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Johnson & Johnson is $282.00, about 6.9% above its October 12 closing price of $263.73
The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 21 three months ago

Reuters Recommended Reads
Oct 12 - Bristol Myers radiopharma cancer drug slows rare tumor progression in study
Oct 13 - UnitedHealth Q3 revenue beats; raises profit forecast

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)